98 related articles for article (PubMed ID: 14977432)
1. Effect of excipients on the stability and aerosol performance of nebulized aviscumine.
Steckel H; Eskandar F; Witthohn K
J Aerosol Med; 2003; 16(4):417-32. PubMed ID: 14977432
[TBL] [Abstract][Full Text] [Related]
2. The effect of formulation variables on the stability of nebulized aviscumine.
Steckel H; Eskandar F; Witthohn K
Int J Pharm; 2003 May; 257(1-2):181-94. PubMed ID: 12711173
[TBL] [Abstract][Full Text] [Related]
3. Effect of cryoprotectants on the stability and aerosol performance of nebulized aviscumine, a 57-kDa protein.
Steckel H; Eskandar F; Witthohn K
Eur J Pharm Biopharm; 2003 Jul; 56(1):11-21. PubMed ID: 12837476
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
Schöffski P; Riggert S; Fumoleau P; Campone M; Bolte O; Marreaud S; Lacombe D; Baron B; Herold M; Zwierzina H; Wilhelm-Ogunbiyi K; Lentzen H; Twelves C;
Ann Oncol; 2004 Dec; 15(12):1816-24. PubMed ID: 15550588
[TBL] [Abstract][Full Text] [Related]
5. Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures.
Elhissi AM; Faizi M; Naji WF; Gill HS; Taylor KM
Int J Pharm; 2007 Apr; 334(1-2):62-70. PubMed ID: 17123757
[TBL] [Abstract][Full Text] [Related]
6. Lyoprotection of aviscumine with low molecular weight dextrans.
Gloger O; Witthohn K; Müller BW
Int J Pharm; 2003 Jul; 260(1):59-68. PubMed ID: 12818810
[TBL] [Abstract][Full Text] [Related]
7. Stabilizing protein formulations during air-jet nebulization.
Albasarah YY; Somavarapu S; Taylor KM
Int J Pharm; 2010 Dec; 402(1-2):140-5. PubMed ID: 20933073
[TBL] [Abstract][Full Text] [Related]
8. Comparison of jet and ultrasonic nebulizer pulmonary aerosol deposition during mechanical ventilation.
Harvey CJ; O'Doherty MJ; Page CJ; Thomas SH; Nunan TO; Treacher DF
Eur Respir J; 1997 Apr; 10(4):905-9. PubMed ID: 9150333
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001).
Bergmann L; Aamdal S; Marreaud S; Lacombe D; Herold M; Yamaguchi T; Wilhelm-Ogunbiyi K; Lentzen H; Zwierzina H;
Eur J Cancer; 2008 Aug; 44(12):1657-62. PubMed ID: 18602257
[TBL] [Abstract][Full Text] [Related]
10. Design principles of liquid nebulization devices currently in use.
Rau JL
Respir Care; 2002 Nov; 47(11):1257-75; discussion 1275-8. PubMed ID: 12425742
[TBL] [Abstract][Full Text] [Related]
11. Physicochemical aspects and efficiency of albuterol nebulization: comparison of three aerosol types in an in vitro pediatric model.
Sidler-Moix AL; Di Paolo ER; Dolci U; Berger-Gryllaki M; Cotting J; Pannatier A
Respir Care; 2015 Jan; 60(1):38-46. PubMed ID: 25516995
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-I aerosol formulations for pulmonary delivery.
Germershaus O; Schultz I; Lühmann T; Beck-Broichsitter M; Högger P; Meinel L
Eur J Pharm Biopharm; 2013 Sep; 85(1):61-8. PubMed ID: 23958318
[TBL] [Abstract][Full Text] [Related]
13. Formulations and nebulizer performance.
O'Riordan TG
Respir Care; 2002 Nov; 47(11):1305-12; discussion 1312-3. PubMed ID: 12425745
[TBL] [Abstract][Full Text] [Related]
14. Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours.
Schöffski P; Breidenbach I; Krauter J; Bolte O; Stadler M; Ganser A; Wilhelm-Ogunbiyi K; Lentzen H
Eur J Cancer; 2005 Jul; 41(10):1431-8. PubMed ID: 15913988
[TBL] [Abstract][Full Text] [Related]
15. Impact of lyoprotectants for the stabilization of biodegradable nanoparticles on the performance of air-jet, ultrasonic, and vibrating-mesh nebulizers.
Beck-Broichsitter M; Kleimann P; Schmehl T; Betz T; Bakowsky U; Kissel T; Seeger W
Eur J Pharm Biopharm; 2012 Oct; 82(2):272-80. PubMed ID: 22820646
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing polycation/siRNA colloidal stability toward aerosol lung delivery.
Steele TW; Zhao X; Tarcha P; Kissel T
Eur J Pharm Biopharm; 2012 Jan; 80(1):14-24. PubMed ID: 21924355
[TBL] [Abstract][Full Text] [Related]
17. Adaptation and performance of an immuno-PCR assay for the quantification of Aviscumine in patient plasma samples.
Adler M; Langer M; Witthohn K; Wilhelm-Ogunbiyi K; Schöffski P; Fumoleau P; Niemeyer CM
J Pharm Biomed Anal; 2005 Oct; 39(5):972-82. PubMed ID: 15982849
[TBL] [Abstract][Full Text] [Related]
18. Nebulization of active pharmaceutical ingredients with the eFlow(®) rapid: impact of formulation variables on aerodynamic characteristics.
Beck-Broichsitter M; Prüfer N; Oesterheld N; Seeger W; Schmehl T
J Pharm Sci; 2014 Aug; 103(8):2585-9. PubMed ID: 24986144
[TBL] [Abstract][Full Text] [Related]
19. Influence of nebulizer type with different pediatric aerosol masks on drug deposition in a model of a spontaneously breathing small child.
Lin HL; Wan GH; Chen YH; Fink JB; Liu WQ; Liu KY
Respir Care; 2012 Nov; 57(11):1894-900. PubMed ID: 22418694
[TBL] [Abstract][Full Text] [Related]
20. Physical properties of antibiotic aerosols produced by jet and ultrasonic nebulizers.
Takanami C; Goto Y
J Aerosol Med; 1990; 3(1):45-52. PubMed ID: 10147674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
